BurnsAdler Licenses Nitronal® IV
Infusion to Laboratorios PiSA
Charlotte, North Carolina, and Guadalajara, Mexico – (March 29, 2004) – BurnsAdler Pharmaceuticals, Inc. (“BurnsAdler”) announced today that it has signed an exclusive seven year import, promotion and distribution agreement with Laboratorios PiSA S.A. de C.V. (“PiSA”) for Nitronal® IV Infusion, a unique presentation of glyceryl trinitrate. Nitronal® IV Infusion is a pre-diluted, isotonic aqueous infusion solution with a glyceryl trinitrate concentration of 1mg/ml. The product will be indicated for the treatment of severe angina pectoris, acute myocardial infarction, acute left-ventricular failure, hypertensive crisis with cardiac decompensation, controlled hypotension, catheter induced coronary spasms and increase of ischemia tolerance during PTCA.
Carolina Cortez, Director of BurnsAdler stated, “We are very pleased to partner with Laboratorios PiSA for the commercialization of Nitronal® IV Infusion in Mexico. PiSA is an acknowledged leader in supplying pharmaceutical products for the Mexican hospital market and we are confident they will be an excellent addition to the international marketing effort for this important product.”
Nitronal is a water-based isotonic solution that does not require dilution prior to use and contains no alcohol, solvents or preservatives. When compared to isosorbide dinitrate or ISDN intravenous solutions, the product also demonstrates many clinically significant benefits which allow physicians to better manage patients pharmacologically. The most significant of these benefits include a statistically significant shorter half-life and the earlier and more predictable termination of haemodynamic effects. Nitronal® IV Infusion reduces heart preload, the most important physiopathological effect in the acute myocardial infarction indication. Nitronal® IV Infusion’s effects generally cease within thirty minutes following the infusion whereas the effects of an ISDN infusion typically lasts between one and two hours. ISDN solutions also demonstrate a higher risk of significant hypotonia, which could lead to serious complications for the infarct patient when compared to Nitronal® IV Infusion.
Laboratorios PiSA is a leading Mexican pharmaceutical company with additional presence in Central and South America. The company manufactures and in-licenses specialty hospital products. Laboratorios PiSA has a portfolio focused on many specialty areas including the Intensive Care Line which is a major priority for the company. Please find additional information about Laboratorios PiSA at www.pisa.com.mx.
BurnsAdler is a specialty pharmaceutical company that in-licenses and promotes products in Europe, South America, Latin America, Canada and the Caribbean. BurnsAdler’s portfolio currently includes products in the following fields: cardiovascular, orthopedic, anti-epileptic and hospital.
For additional information about this news release contact Carolina Cortez at +1.704.552.8410 Ext. 225. Find additional information about BurnsAdler at www.burnsadler.com.